<SEC-DOCUMENT>0001004878-18-000071.txt : 20180404
<SEC-HEADER>0001004878-18-000071.hdr.sgml : 20180404
<ACCEPTANCE-DATETIME>20180404163754
ACCESSION NUMBER:		0001004878-18-000071
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20180404
DATE AS OF CHANGE:		20180404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-186103
		FILM NUMBER:		18737707

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prosuppswrt186103april-18.txt
<TEXT>

PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplements dated December            Registration No. 333-186103
 19 and December 26, 2013)



                               CEL-SCI CORPORATION
                                Series S Warrants



     On April 3, 2018 the exercise price of the Company's  outstanding  Series S
warrants  (CUSIP number  150837177),  that are publicly  traded under the symbol
"CVM WS" on the NYSE  American,  was  changed to $1.75 per share  until June 11,
2018.  After this date,  the exercise price will revert back to $31.25 per share
of common stock.  As a result of the reverse stock split which became  effective
on the NYSE  American on June 15,  2017,  25 Series S warrants  are  required to
purchase one share of common stock.  The Series S warrants expire on October 11,
2018.





























                    Prospectus Supplement dated April 3, 2018
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
